BioSpace News Archive

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the preliminary results of its rights offering which expired at 5:00 P.M. Eastern Time on August 24, 2022.

CDx Diagnostics, Inc. announced that the WATS3D diagnostic platform has been incorporated in the American Gastroenterological Association Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review, published in Clinical Gastroenterology and Hepatology.

Assertio Holdings, Inc. announced that it has closed its offering of $70 million aggregate principal amount of 6.50% convertible senior notes due 2027, including the full exercise of the option to purchase $10 million of additional notes granted by Assertio to the initial purchaser.

Lunit (KRX: 328130.KQ), a leading medical AI provider, today announced that it received commercial approval in Taiwan for Lunit INSIGHT MMG, the company’s AI solution for mammography analysis.

B.More Inc. today announced that the U.S. Food and Drug Administration has approved its IND application to begin a Phase 2b clinical trial to determine the efficacy and safety of synthetic psilocybin (SYNP-101) in treating patients with alcohol use disorder (AUD).

Mind Medicine today announced first patient dosing in its Phase 2b dose-optimization trial of MM-120, a pharmaceutically optimized form of lysergic acid diethylamide (LSD), for the treatment of Generalized Anxiety Disorder (GAD).

BiondVax Pharmaceuticals Ltd. today published its financial results for the quarter ended June 30, 2022 and provided a business update.

Prestige Medical Imaging announced today that it has completed acquisitions of MedServ Plus and XRV Healthcare to the PMI business platform.

Cybin to Participate in the H.C. Wainwright 24th Annual Global Investment Conference.

AltrixBio , an emerging early-stage biotech startup, is presenting an abstract on LuCI™, a repurposed pill that adheres to the gastrointestinal (GI) tract for controlled GI targeting.